Synonyms: compound 139 [WO2019160882A1] | GS-4224 | GS4224 | PD-1/PD-L1-IN 7
Compound class:
Synthetic organic
Comment: We obtained the chemical structure for evixapodlin from WHO Proposed list 125 of July 2021. The INN record describes it as a programmed cell death ligand 1 (PD-L1) inhibitor. Evixapodlin is one of the chemical structures that is claimed in Gilead Sciences' patent WO2019160882A1 (compound number 139) [1]. It was developed as an alternative to monocloncal antibody PD-L1/PD-1 interaction inhibitors, for potential anticancer and antiviral activities. First disclosures at the ACS meeting in Chicago in 2022 mapped evixapodlin to Gilead's clinical lead GS-4224. GS-4224 is orally bioavailable.
|
|
References |
1. Aktoudianakis E, Cho A, Du Z, Graupe M, Lad LT, Machicao Tello PA, Medley JW, Metobo SE, Mukherjee PK, Naduthambi D et al.. (2019)
Pd-1/pd-l1 inhibitors. Patent number: WO2019160882A1. Assignee: Gilead Sciences, Inc.. Priority date: 13/02/2018. Publication date: 22/08/2019. |